LITTLETON, Colo., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ('OSA') and other health conditions related to breathing and sleep disorders, today announced that it has entered into a definitive Mutual Stock Purchase and Asset Exchange Agreement to acquire an 11% fully diluted equity interest in SOD Sciences, Inc.

科罗拉多州利特尔顿，2026年10月15日（环球电讯社）——Vivos Therapeutics, Inc.（“Vivos”或“公司”）（纳斯达克股票代码：VVOS）是一家专注于开发和商业化阻塞性睡眠呼吸暂停（OSA）及其他与呼吸和睡眠障碍相关健康问题的诊断和治疗方法的医疗器械及医疗服务公司。该公司今日宣布，已签署一份具有约束力的《相互股票购买与资产交换协议》，以收购SOD Sciences, Inc. 11%的完全稀释股权权益。

and a 50% undivided co-ownership interest in SOD’s proprietary pseudohypoxia early-warning test, in exchange for 12,000 shares of newly created Series C Convertible Preferred Stock with an aggregate stated value of $12 million. Closing is subject to customary conditions, including auditor concurrence, consent of the holder of the Company’s Series B Non-Convertible Preferred Stock, and Nasdaq notification, and is expected to occur on or about October 15, 2026.

以及获得SOD公司专有的伪缺氧早期预警测试的50%不可分割共有权益，以换取12,000股新设立的C系列可转换优先股，其总声明价值为1,200万美元。交易交割须满足惯例条件，包括审计师同意、公司B系列不可转换优先股持有人的同意，以及向纳斯达克发出通知，预计将于2026年10月15日左右完成。

The agreement opens the door for potentially important collaboration and research opportunities with the Cleveland Clinic in Weston, Florida, and a marketing relationship with American Health Associates (AHA), a national medical services provider to patients housed in approximately 3,000 assisted living and nursing home facilities across 25 states..

该协议为与位于佛罗里达州韦斯顿的克利夫兰诊所开展潜在的重要合作和研究机会打开了大门，并与美国健康协会（AHA）建立了营销合作关系。AHA 是一家全国性医疗服务提供商，为遍布 25 个州的约 3,000 家辅助生活和护理机构中的患者提供服务。

No cash consideration is payable under the agreement. The Company believes the transaction, if closed and if the preferred stock is classified in permanent stockholders’ equity as anticipated, would increase reported stockholders’ equity and support the Company’s efforts to regain compliance with Nasdaq rules.

根据协议，无需支付现金对价。公司认为，若交易完成且优先股按预期被归类为永久性股东权益，则将增加报告的股东权益，并支持公司为恢复符合纳斯达克规则所作的努力。

In the event the Company clears that milestone, management intends to seek to raise sufficient capital to continue expanding operations in its efforts to achieve its near-term objectives of positive cash flow and profitability in early 2027. Any determination of compliance remains subject to Nasdaq’s assessment..

若公司达成该里程碑，管理层计划寻求筹集足够资金，以继续扩大运营，努力实现其在2027年初实现正向现金流和盈利的近期目标。任何合规性认定仍须接受纳斯达克的评估。

Vivos Chairman and CEO R. Kirk Huntsman stated, “We have been working on this transaction for months and believe the total value accretion to Vivos has the potential to far exceed the immediate dilution from the issuance of the preferred shares. Upon closing, we expect to pursue collaboration efforts contemplated by SOD’s existing relationship with Cleveland Clinic Weston and with American Health Associates, subject to negotiation and execution of definitive agreements and satisfaction of applicable regulatory and clinical requirements.

Vivos 董事长兼首席执行官 R. Kirk Huntsman 表示：“我们已为此交易努力数月，并相信该交易为 Vivos 带来的整体价值增值潜力将远远超过因发行优先股而造成的即时稀释影响。在交易完成后，我们预计将推进 SOD 与克利夫兰诊所韦斯顿分院以及与美国健康协会（American Health Associates）现有关系所设想的合作努力，但须以谈判并签署最终协议、以及满足适用的监管和临床要求为前提。”

It is contemplated that Vivos will retain 80% of the contribution margin on sales of Vivos products through those channels, and that the parties will share contribution margin 50/50 on sales of the jointly owned test. That relationship is expected to be solidified in the coming weeks and underway in early 2027, potentially leading to significant new and recurring revenue and high margins opportunities.”.

预计Vivos将保留通过上述渠道销售Vivos产品所产生的80%的贡献毛利，而双方将对共同拥有的测试项目的销售额按50/50的比例分享贡献毛利。该合作关系预计将在未来几周内得到巩固，并于2027年初开始实施，有望带来显著的新增及经常性收入和高利润率机会。

'Sleep apnea is not just a breathing problem. It is a cellular oxygen problem, and the cell remembers,' said Joseph M. Salvani, Chief Executive Officer of SOD Sciences. 'The pseudohypoxia signature tells a patient that their cells have been primed for chronic disease, and ReBalU potentially gives them a way to measure it, treat it, and assess change.

“睡眠呼吸暂停不仅仅是一个呼吸问题。它是一个细胞层面的氧气问题，而细胞会‘记住’这一状态，”SOD Sciences 首席执行官约瑟夫·M·萨尔瓦尼表示。“假性缺氧特征提示患者，其细胞已处于慢性疾病的预备状态，而 ReBalU 有望为他们提供一种测量、治疗并评估变化效果的手段。”

Vivos has the patients, the FDA‑cleared devices, and the home oxygen test. We have the protocol, the channels, and the science. Together we believe we can turn sleep medicine into an early warning system for chronic disease in America.'.

Vivos 拥有患者资源、获美国食品药品监督管理局（FDA）批准的器械以及居家氧气检测方案。我们拥有诊疗规范、渠道和科学依据。我们相信，通过携手合作，可以将睡眠医学转变为美国慢性疾病的早期预警系统。

Channel Relationships

渠道关系

SOD holds a Memorandum of Understanding with Cleveland Clinic Weston that contemplates an IRB-approved study comparing Vivos' FDA‑cleared CARE oral appliances with CPAP for intermittent hypoxia and a potential commercial program relating to existing CPAP patients. This agreement potentially brings that channel, and the AHA national network directly to Vivos.

SOD 与克利夫兰诊所韦斯顿分院签署了一份谅解备忘录，拟开展一项经机构审查委员会（IRB）批准的研究，比较 Vivos 公司获美国食品药品监督管理局（FDA） clearance 的 CARE 口腔矫治器与持续气道正压通气（CPAP）在治疗间歇性低氧方面的效果，并探讨针对现有 CPAP 用户的潜在商业化项目。该协议有望为 Vivos 直接接入这一渠道以及美国心脏协会（AHA）的全国网络。

No assurance can be given that definitive agreements will be executed or that any commercial activity will result..

无法保证最终协议将会签署，也无法保证会产生任何商业活动。

Economics of the Test

测试的经济学

The test pairs SOD's ReBalU genotype and biomarker panel with a measurement of nocturnal oxygen desaturation and recovery. Vivos' at‑home oxygen desaturation and re‑emergence test is a potentially synergistic instrument for that measurement. The result identifies individuals whose cells carry the pseudohypoxia signature of priming for further chronic disease, including cancer, while there is still time to act..

该测试将SOD的ReBalU基因型和生物标志物组合与夜间血氧饱和度下降及恢复的测量相结合。Vivos的居家血氧饱和度下降与复升测试是用于该测量的一种具有潜在协同效应的工具。检测结果可识别出那些细胞携带假性缺氧特征、处于进一步慢性疾病（包括癌症）前期状态的个体，从而为及时干预留出时间。

The agreement gives Vivos a 50% undivided co-ownership interest in the test and related intellectual property and a contractual right to 50% of the contribution margin on sales of the jointly owned test through any channel. Separately, Vivos will hold at least an 11% fully diluted equity interest in SOD Sciences.

该协议赋予Vivos对测试及相关知识产权50%的不可分割共有权益，以及通过任何渠道销售共同拥有的测试所获得的贡献毛利中50%的合同权利。此外，Vivos将持有SOD Sciences至少11%的完全稀释股权权益。

These interests are distinct: the test participation is governed by the commercial arrangements, while the minority stake represents ownership in SOD..

这些权益性质不同：测试参与受商业协议约束，而少数股权则代表对SOD的所有权。

Following closing, the parties will negotiate a joint marketing or distribution agreement and a separate agreement addressing marketing of the ReBalU Protocol to U.S. sleep-testing centers. Sleep testing services are expected to remain outside the joint marketing arrangements, and Vivos would retain the associated revenue.

交易完成后，双方将协商达成一项联合营销或分销协议，以及一份针对向美国睡眠检测中心推广ReBalU协议的独立协议。睡眠检测服务预计仍将排除在联合营销安排之外，Vivos公司将保留相关收入。

Contribution margin should not be equated with consolidated revenue, net income or cash flow..

贡献毛利不应与合并收入、净利润或现金流量等同。

Any revenue or margin from the test or related products will depend on clinical validation, regulatory status, channel execution, testing volume, realized pricing, and the costs allocated under the agreements. Establishing the clinical utility of the test is a central requirement for the opportunity.

该检测产品或相关产品的任何收入或利润将取决于临床验证、监管状态、渠道执行、检测量、实际定价以及根据协议分摊的成本。确立该检测的临床效用是实现这一商业机会的核心要求。

The announcement does not establish that the test predicts cancer or future chronic disease, or that ReBalU prevents those conditions. Vivos’ oral-appliance FDA clearances do not extend to this test..

该公告并未证实该测试能够预测癌症或未来的慢性疾病，也未证实ReBalU能够预防这些疾病。Vivos公司的口腔矫治器获得的FDA许可并不涵盖此项测试。

“Our aim is to build a commercial program whose clinical usefulness and operating performance can be measured,” said Joseph M. Salvani, Chief Executive Officer of SOD Sciences. “Combining our platform with Vivos’ capabilities creates a potential opportunity; validation and disciplined implementation will determine the results.”.

SOD Sciences 首席执行官约瑟夫·M·萨尔瓦尼表示：“我们的目标是打造一个可衡量其临床实用性和运行性能的商业化项目。将我们的平台与 Vivos 的能力相结合，创造了潜在的机遇；而验证和严谨的实施将决定最终成果。”

Transaction Terms and Closing

交易条款与交割

Vivos will issue 12,000 shares of Series C Convertible Preferred Stock with an aggregate stated value of $12 million. The preferred stock is convertible into shares of common stock at a fixed conversion price of $0.15 per share, representing up to 80 million shares in the aggregate, subject to a 19.99% exchange cap pending stockholder approval and a 4.99% beneficial ownership limitation (waivable to 9.99%).

Vivos 将发行 12,000 股 C 系列可转换优先股，总声明价值为 1,200 万美元。该优先股可按每股 0.15 美元的固定转换价格转换为普通股，总计最多可转换为 8,000 万股，但须遵守待股东批准的 19.99% 交换上限以及 4.99% 的实益所有权限制（可豁免至 9.99%）。

Conversion above the exchange cap requires stockholder approval, which the Company intends to seek in connection with its next annual general meeting. The preferred stock has no redemption right, cash-settlement requirement or price-reset provision. No warrants are being issued, and no cash consideration is payable at closing..

超过交换上限的转换需获得股东批准，公司拟在下次年度股东大会上寻求该批准。优先股不含赎回权、现金结算要求或价格重置条款。公司不发行任何认股权证，且在交割时无需支付现金对价。

The Company expects the preferred stock to be classified in permanent stockholders’ equity and the acquired interests to be recorded at fair value, subject to completion of a final valuation and concurrence of the Company’s independent registered public accounting firm. The Company expects an increase in reported stockholders’ equity that could support its efforts to regain compliance with Nasdaq’s minimum stockholders’ equity requirement.

公司预计优先股将被归类为永久性股东权益，所收购的权益将以公允价值入账，但须以完成最终估值并获得公司独立注册会计师事务所的认可为前提。公司预计报告中的股东权益将有所增加，这有助于其努力恢复对纳斯达克最低股东权益要求的合规性。

The amount of that increase and any determination of compliance remain subject to the applicable accounting review and Nasdaq’s assessment..

该增长幅度以及任何合规性认定仍须接受适用的会计审查及纳斯达克的评估。

About Vivos Therapeutics

关于 Vivos Therapeutics

Vivos Therapeutics, Inc. (Nasdaq: VVOS) is a medical technology and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults.

Vivos Therapeutics, Inc.（纳斯达克股票代码：VVOS）是一家医疗科技与医疗服务公司，专注于开发和商业化创新的诊断与治疗方法，服务于因某些牙面畸形（如成人阻塞性睡眠呼吸暂停（OSA）和打鼾）而导致呼吸和睡眠问题的患者。

Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. For more information, visit www.vivos.com..

Vivos 的设备已获得美国食品药品监督管理局（FDA）的批准，适用于所有严重程度的成人阻塞性睡眠呼吸暂停（OSA）患者，以及6至17岁儿童中中度至重度 OSA 患者。欲了解更多信息，请访问 www.vivos.com。

About SOD Sciences

关于 SOD 科学

SOD Sciences, Inc. is a precision-health company and the developer of the ReBalU Protocol, which combines genetic and biomarker testing with a nutrition-based program and follow-up testing. SOD is also developing applications of its platform related to pseudohypoxia.

SOD Sciences, Inc. 是一家精准健康公司，也是 ReBalU 方案的开发者，该方案将基因和生物标志物检测与基于营养的计划及后续检测相结合。SOD 还在开发其平台在假性缺氧相关领域的应用。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性陈述的警示说明

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements regarding the satisfaction of the closing conditions and the timing and occurrence of the Closing; the expected benefits of the transaction with SOD; the negotiation and execution of the Joint Marketing Agreement, the Sleep Center Agreement and the definitive channel agreements with American Health Associates and Cleveland Clinic Weston; the anticipated accounting treatment of the transaction; the Company’s compliance with Nasdaq continued listing requirements; the proposed reverse stock split; and the stockholder approval to be sought under Nasdaq Listing Rule 5635(a).

本公告包含1995年《私人证券诉讼改革法》所定义的“前瞻性陈述”。这些陈述包括：关于成交条件满足情况以及交割的时间和发生情况的陈述；与SOD交易预期带来的利益的陈述；与美国健康协会（American Health Associates）和克利夫兰诊所韦斯顿分院（Cleveland Clinic Weston）就联合营销协议、睡眠中心协议以及最终渠道协议进行的谈判及签署情况的陈述；对该交易预期会计处理的陈述；公司遵守纳斯达克持续上市要求的情况；拟议的反向股票分割；以及根据纳斯达克上市规则5635(a)将寻求股东批准的事项。

Words such as “expects,” “intends,” “believes,” “potential,” “contemplates” and similar expressions identify these statements..

“预期”、“打算”、“相信”、“潜在”、“考虑”等词语及类似表述用于识别这些陈述。

These statements are subject to risks and uncertainties that could cause actual results to differ materially, including the risk that the closing conditions are not satisfied and the transaction does not close; that the anticipated benefits of the transaction are not realized; that the definitive post-closing agreements are not executed on the anticipated terms or at all; that the Company’s independent registered public accounting firm or Nasdaq reaches conclusions different from those anticipated; that stockholder approval is not obtained; that clinical or regulatory requirements are not met; that dilution from conversion exceeds expectations; that the Company does not regain or maintain Nasdaq compliance; and the other risks described in the Company’s SEC filings, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and its other SEC filings.

这些陈述受风险和不确定性的影响，可能导致实际结果与预期存在重大差异，包括：交割条件未能满足且交易未能完成的风险；交易的预期效益未能实现的风险；最终交割后协议未能按预期条款签署或根本未签署的风险；公司独立注册公共会计师事务所或纳斯达克得出的结论与预期不同的风险；未能获得股东批准的风险；未能满足临床或监管要求的风险；因转换导致的稀释超过预期的风险；公司未能重新符合或维持纳斯达克合规要求的风险；以及公司在美国证券交易委员会（SEC）文件中描述的其他风险，包括其最新的10-K表格年度报告、10-Q表格季度报告以及其他SEC文件。

No assurance can be given that any anticipated commercial or financial benefits will be realized. Vivos undertakes no obligation to update forward-looking statements except as required by law..

无法保证任何预期的商业或财务利益将会实现。Vivos 没有义务更新前瞻性陈述，除非法律另有要求。

Investor and Media Contacts

投资者与媒体联系人

Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc.

Investor Relations: investors@vivoslife.com

投资者关系：investors@vivoslife.com